Company intelligence / Profile preview

Follicle Pharma

Ownership: Private
Development stage: Phase 2

Overview

Currently conducting a Phase 1 clinical trial (NCT05611593) to assess the safety, tolerability, and usability of FOL100 lotion compared to oral finasteride for androgenetic alopecia treatment. The study began on October 20, 2022, and is currently recruiting participants. The trial aims to investigate whether local topical administration of FOL100 lotion is safe and does not cause local or systemic adverse events, while also indicating effectiveness compared to oral finasteride 1mg.[2][5]

Therapeutic areas: Dermatology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

2 assets

FOL-100

1 more asset in the full pipeline.

Beyond the preview

Go deeper on Follicle Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Follicle Pharma.